Attached files
| file | filename |
|---|---|
| EX-23.1 - EX-23.1 - Kaleido Biosciences, Inc. | kldo-ex231_233.htm |
| EX-31.1 - EX-31.1 - Kaleido Biosciences, Inc. | kldo-ex311_231.htm |
| EX-21.1 - EX-21.1 - Kaleido Biosciences, Inc. | kldo-ex211_315.htm |
| 10-K - 10-K - Kaleido Biosciences, Inc. | kldo-10k_20191231.htm |
| EX-32.2 - EX-32.2 - Kaleido Biosciences, Inc. | kldo-ex322_229.htm |
| EX-31.2 - EX-31.2 - Kaleido Biosciences, Inc. | kldo-ex312_232.htm |
| EX-10.13 - EX-10.13 - Kaleido Biosciences, Inc. | kldo-ex1013_345.htm |
| EX-4.3 - EX-4.3 - Kaleido Biosciences, Inc. | kldo-ex43_314.htm |
Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Alison Lawton, Chief Executive Officer of Kaleido Biosciences, Inc. (the “Company”), do hereby certify, pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that, to the best of my knowledge:
(1) the Annual Report on Form 10-K of the Company for the year ended December 31, 2019 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: March 2, 2020